Document is current
Any future updates will be listed below
-
Authors
Kamiya, Hideki
Suzuki, Ryo
Wada, Jun
Deguchi, Takahisa
Himeno, Tatsuhito
Yamamoto, Shuhei
Toyama, Taiki
Nakamura, Jiro
-
Funding
Funding for this research was provided by:
Daiichi-Sankyo
- License Information
-
More Information
Article History
Received: 28 July 2025
Accepted: 30 September 2025
First Online: 24 October 2025
Declarations
:
: Hideki Kamiya has received speaker honoraria from Abbott Japan LLC., Arkray, Inc., Astellas Pharma Inc., AstraZeneca K.K., Bayer Yakuhin, Ltd., Nippon Boehringer Ingelheim Co., Ltd., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., EA Pharma Co., Ltd., Eli Lilly Japan K.K., Eisai Co., Ltd., Fukuda Denshi Co., Ltd., GlaxoSmithKline K.K., Kissei Pharmaceutical Co., Ltd., Kowa Co., Ltd., Kyowa Kirin Co., Ltd., Novartis Pharma K.K., Novo Nordisk Pharma Ltd., Mitsubishi Tanabe Pharma Corp., MSD K.K., Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Sanofi K.K., Sumitomo Pharma Co., Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., Taisho Pharmaceutical Co., Ltd., Teijin Pharma Ltd., and Viatris Inc.; and grant support from Nippon Boehringer Ingelheim Co., Ltd., CBC Co., Ltd., Daiichi Sankyo Co., Ltd., EA Pharma Co., Ltd., Eli Lilly Japan K.K., Fukuda Denshi Co., Ltd., Kissei Pharmaceutical Co., Ltd. Kowa Co., Ltd., Kyowa Kirin Co., Ltd., MSD K.K., Mochida Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Parexel International Corp., Sanwa Kagaku Kenkyusho Co., Ltd., Sumitomo Pharma Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd. Ryo Suzuki has received a lecture fee from Daiichi Sankyo Co., Ltd. Jun Wada has received speaker honoraria from AstraZeneca K.K., Bayer Yakuhin, Ltd., Nippon Boehringer Ingelheim Co., Ltd., Daiichi Sankyo Co., Ltd., Kyowa Kirin Co., Ltd., Novo Nordisk Pharma Ltd., and Mitsubishi Tanabe Pharma Corp.; and grant support from Abbott Japan LLC., Bayer Yakuhin, Ltd., Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Sumitomo Pharma Co., Ltd., and Mitsubishi Tanabe Pharma Corp. Takahisa Deguchi has received a lecture fee from Daiichi Sankyo Co., Ltd. Tatsuhito Himeno has no COI to be declared. Shuhei Yamamoto and Taiki Toyama are employees of Daiichi Sankyo Co., Ltd. Jiro Nakamura has received a lecture fee from Daiichi Sankyo Co., Ltd.
: The study has been approved by the Certified Review Board of Hattori Clinic (CRB3180027; approval date, 20/December/2024) and registered in the Japan Registry of Clinical Trials (jRCTs031240623 registered 20/January/2025). The study will be conducted in accordance with the Ethical Guidelines for Life Science and Medical Research Involving Human Subjects, the Act on the Protection of Personal Information, and the Declaration of Helsinki (as revised in 2013). The study will also be conducted in accordance with the Clinical Trials Act in Japan, under which clinical research is only required to undergo a central ethical review. Written informed consent will be obtained from each patient. No permissions are required for assessment scales other than EQ-5D-5L. The permission for use of EQ-5D-5L was obtained prior to study [ ].
